Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Spotlights AAA Device, Thermocool Extensions During Analyst Meeting

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson is looking to the Nevo sirolimus-eluting stent and entry into fast-growing endovascular device segments, such as the abdominal aortic aneurysm market, to restore growth in its struggling Cordis unit

You may also be interested in...



Cordis Launches Low-Profile Incraft AAA Stent Graft In Europe And Canada

The J&J division has been talking-up Incraft as a potentially major innovation in the treatment abdominal aortic aneurysms for several years.

And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market

The first company to enter the drug-eluting stent market will now be the first to depart.

And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market

The first company to enter the drug-eluting stent market will now be the first to depart.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029003

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel